Lavipharm Balance Sheet Health
Financial Health criteria checks 4/6
Lavipharm has a total shareholder equity of €42.8M and total debt of €20.8M, which brings its debt-to-equity ratio to 48.6%. Its total assets and total liabilities are €114.8M and €72.0M respectively. Lavipharm's EBIT is €4.4M making its interest coverage ratio 2.3. It has cash and short-term investments of €8.4M.
Key information
48.6%
Debt to equity ratio
€20.80m
Debt
| Interest coverage ratio | 2.3x |
| Cash | €8.44m |
| Equity | €42.77m |
| Total liabilities | €72.02m |
| Total assets | €114.79m |
Financial Position Analysis
Short Term Liabilities: LAVI's short term assets (€45.7M) exceed its short term liabilities (€35.8M).
Long Term Liabilities: LAVI's short term assets (€45.7M) exceed its long term liabilities (€36.2M).
Debt to Equity History and Analysis
Debt Level: LAVI's net debt to equity ratio (28.9%) is considered satisfactory.
Reducing Debt: LAVI had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: LAVI's debt is not well covered by operating cash flow (1.4%).
Interest Coverage: LAVI's interest payments on its debt are not well covered by EBIT (2.3x coverage).